Inotrem S.A.’s €39 Million Series B Financing Round


Goodwin and Jones Day advised on the deal

Jones Day advised Inotrem S.A., a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €39 million (US$43 million) Series B round of financing led by Morningside Ventures and joined by Invus as well as historical investors including Andera Partners, Sofinnova Partners, and BiomedInvest.

Goodwin advised the investors with Thomas Dupont-Sentilles and Félicien Bardsley.

Jones Day team was led by Geoffroy Pineau-Valencienne (Picture).

Involved fees earner: Félicien Bardsley – Goodwin Procter; Thomas Dupont-Sentilles – Goodwin Procter; Geoffroy Pineau-Valencienne – Jones Day;

Law Firms: Goodwin Procter; Jones Day;

Clients: Andera Partners; BioMedPartners AG; Inotrem SA; Invus; Morningside Venture Capital; Sofinnova Partners;